Trans-resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats

Journal of Agricultural and Food Chemistry

Volumn 58, Issue 13, 2010, Pages 8104-8110

  Alfaras, Irene ^a   Emilia Juan M ^a   Planas, Joana M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aberrant crypt foci; Colon cancer; Dihydroresveratrol; Mucin depleted foci; Trans resveratrol

Indexed keywords

1,2 DIMETHYLHYDRAZINE; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLON; COLON TUMOR; DISEASE MODEL; DRUG EFFECT; HUMAN; MALE; METABOLISM; PATHOLOGY; PRECANCER; RAT; SPRAGUE DAWLEY RAT; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DRUG EFFECTS;

1,2-DIMETHYLHYDRAZINE; ANIMALS; COLON; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

RATTUS;

EID: 77953626763     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf100702x     Document Type: Article

References (37)

1. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 2006, 5, 493-506.
2. Bishayee, A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev. Res. (Philadelphia, PA) 2009, 2, 409-418.
3. Kulinle, G.; Spencer, J. P.; Chowrimootoo, G.; Schroeter, H.; et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronic. Biochem. Biochwm. Res. Commun. 2000, 272, 212-217.
4. Sabolovic, N.; Humbert, A. C.; Radominska-Pandya, A.; Magdalou, J. Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm, Drug. Dispos. 2006, 27, 181-189.
5. Juan, M. E.; González-Pons, E.; Planas, J. M. Multidrug resistance proteins restrain the intestinal absorption of of trans-resveratrol. J. Nutr. 2010, 140, 489-495.
6. Juan, M. E.; Wenzel, U.; Daniel, H.; Planas, J. M. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J. Aeric. Food Chem. 2008, 50, 4813-4818.
7. Liang, Y. C.; Tsai, S. H.; Chen, L.; Lin-Shiau, S. Y.; Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol. 2003, 65, 1053-1060.
8. Colin, D.; Gimazane, A.; Lizard, G.; Izard, J. C.; et al. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5-fluorouracil sensitivity in human derived colon cancer cells. Int. J. Cancer 2009, 124, 2780-2788.
9. Hwang, J. T.; Kwak, D. W.; Lin, S. K.; Kim, H. M.; et al. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann. N.Y. Acad. Sci. 2007, 1095, 441-448.
10. Trincheri, N. F.; Nicotra, G.; Folio, C.; Castino, R.; Isidoro, C. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 2007, 28, 922-931.
11. Park, J. W.; Woo, K. J.; Lee, J. T.; Lim, J. H.; et al. Resveratrol induces pro-apoptotic endoplasmic reticulum stress in human colon cancer cells. Oncol. Rep. 2007, 18, 1269-1273.
12. Woo, K. J.; Lee, T. J.; Lee, S. H.; Lee, J. M.; et al. Elevated gadd153/ chop expression during resveratrol-induced apoptosis in human colon cancer cells. Biochem, Pharmacol. 2007, 73, 68-76.
13. Schneider, Y.; Duranton, B.; Gossé, F.; Schleiffer, R.; et al. Resveratrol inhibits intestinal tumorigenesis and modulates host-defenserelated gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer 2001, 39, 102-107.
14. Sengottuvelan, M.; Viswanathan, P.; Nalini, N. Chemopreventive effect of trans-resveratrol, a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 2006, 27, 1038-1046.
15. Juan, M. E.; Maijó, M.; Planas, J. M. Quantification of transresveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm, Biomed, Anal. 2010, 51, 391-398.
16. Validation of compendial methods. In The United States Pharmacopeia and The National Formulary, USP32-NF27; The United. States Pharmacopeial Convention: Rockville, MD, 2009; pp. 733-736.
17. Bird, R. P. Observation and quantification of aberrant crypts in the murie colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 1987, 37, 147-151.
18. Caderni, G.; Femia, A. P.; Giannini, A.; Favuzza, A.; et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: Correlation with carcinogenesis. Cancer Res. 2003, 63, 2388-2392.
19. Juan, M. E.; Vinardell, M. P.; Planas, J. M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 2002, 132, 257-260.
20. Bansal, S.; DeStefano, A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007, 9, E109-E114.
21. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann, Oncol. 2007, 18, 581-592.
22. Cummings, J. H.; Bingham, S. A. Diet and the prevention of cancer. BMJ 1998. 317. 1636-1640.
23. Watson, A. J. An overview of apoptosis and the prevention of colorectal cancer. Crit. Rev. Oncol. Hematol. 2006, 57, 107-121.
24. Marier, J. F.; Vachon, P.; Gritsas, A.; Zhang, J.; et al. Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol, Exp. Ther. 2002, 302, 369-373.
25. Sakamoto, H.; Yokota, H.; Kibe, R.; Sayama, Y.; Yuasa, A. Excretion of bisphenol A-glucuronide into the small intestine and deconjugation in the cecum of the rat. Biochim, Biophys. Acta 2002, 1573, 171-176.
26. Kong, H.; Kim, Y.; Lee, Y.; Choi, B. Sulfate-conjugated methylprednisolone: Evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. J. Drug Tarnt 2009. 17, 159-167.
27. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
28. Wang, D.; Hang, T.; Wu, C.; Liu, W. Identification of the major metabolites of resveratrol in rat urine by HPLC-MS/MS. J. Chromatogr., B; Anal Techml. Biomed, Lift Sci. 2005, 829, 97-106.
29. Jung, C. M.; Heinze, T. M.; Schnackenberg, L. K.; Mullis, L. B.; et al. Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol, Lett, 2009, 297, 266-273.
30. Stivala, L. A.; Savio, M.; Carafoli, F.; Perucca, P.; et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 2001, 276, 22586-22594.
31. Cardile, V.; Lombardo, L.; Spatafora, C.; Tringali, C. Chemoenzymatic synthesis and cell-growth inhibition activity of resveratrol analogues. Bioorg, Chem. 2005, 33, 22-33.
32. Femia, A. P.; Caderni, G. Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products. Planta Med. 2008, 74, 1602-1607.
33. Tessitore, L.; Davit, A.; Sarotto, I.; Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21, 1619-1922.
34. Sengottuvelan, M.; Deeptha, K.; Nalini, N. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazinc-induced colon carcinogenesis. Nutrition 2009, 25, 11, 69-1176.
35. Sengottuvelan, M.; Nalini, N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazinetreated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br. J. Nutr. 2006, 96, 145-153.
36. Ziegler, C. C.; Rainwater, L.; Whelan, J.; McEntee, M. F. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J. Nutr. 2004, 134, 5-10.
37. Sale, S.; Tunstall, R. G.; Ruparelia, K. C.; Potter, G A.; et al. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer 2005, 115, 194-201.